Shanghai Pharmaceuticals 3.8 billion to acquire medical assets 2% higher today

NetEase Finance December 15 News Shanghai Medicine (601607. SH) announced today that the company paid 1.487 billion cash to buy the pharmaceutical group's antibiotic business and assets at the heart of the New Asia Pharmacy, a year earlier than the deadline for restructuring commitments.　　At the same time, the company funded 2.328 billion yuan acquisition of Citic Pharmaceutical Industrial Co., Ltd. 65.24% controlled equity breakthrough progress, and signed a formal share purchase agreement. New Asia pharmaceutical industry is the country's first batch of 50 modern, in line with the GMP production requirements of the comprehensive pharmaceutical Base, the division of Better governance, good business management, financial situation is stable.　　Xinhua Kang Medicine As the pharmaceutical group antibiotics Sales platform, responsible for the new Asia Medicine and the new pioneer pharmaceutical products in the Shanghai region sales. In 2009, the pharmaceutical group made a commitment to the vast majority of investors in the reorganization of the major assets in Shanghai, and the reorganization of the antibiotic business would be completed by December 31, 2011. Through this antibiotic business reorganization, medicine group's pharmaceutical assets business completed the overall listing.　　After the completion of the antibiotic business reorganization, the pharmaceutical group antibiotic business all injected into the company, is conducive to resolving with the pharmaceutical group in the field of antibiotic business potential competition, and reduce related transactions.　　2009, the pharmaceutical group antibiotic business in the ceftriaxone, Cefotaxime and cephalosporins, such as 3 sales revenue over billion, another includes Cefuroxime, cephalosporins and other products in the forefront of the domestic market, the acquisition will improve the company's existing product structure, increase the company's pharmaceutical industry key varieties, enhance the company's product competitiveness. Shanghai Medicine issued a notice on November 30, said the company will acquire CHS control of the stake, has been registered on November 29 through its Caimas, Is. wholly-owned subsidiary of the Real medical technology as a takeover entity, the acquisition of Northernlightventurecapitalⅱ,　　Ltd., which holds a stake in the chs2.63354%, and an irrevocable and exclusive letter of intent with the NEA China Fund, the Lilly Asia Venture Fund and the chs55.45% Fund, will acquire a stake in the private equity fund and will determine the final transaction price after due diligence. According to the Shanghai Medicine announced today, in addition to the above transaction completion of the final pricing, Shanghai Medicine and the acquisition of Biomedicalsciencesinvestmentfundpteltd and Sagamorebioventures, LLC. Two shareholders are the shares of the chs7.15% held.　　At this point, the acquisition and formal signing of the agreement on the purchase of shares of the CHS six fund shares of the total price of the transaction of 2.328 billion yuan, after the completion of the transaction, Shanghai Medicine will control the holding of chs65.24% equity. Shanghai Medicine Today Gaokaigao go, the highest increase in the plate reached 5.51%, the afternoon contraction narrowed, closing the price of 23.68 yuan, or 1.98%, deal 499 million Yuan, is the lastAbout twice times the trading day. Related news: Shanghai Pharmaceutical Implementation of the reorganization of the commitment of antibiotics business injection finalized 3.8 billion Hao buy two assets overall listing